CAR-T therapies have been licensed in the UK since 2018 for the treatment of B cell lymphoma. But with positive results emerging for their use in multiple myeloma, and the promise of potential in solid tumours, excitement around CAR-T continues to grow.
Read this story at Pharmaceutical Journal.
Like this:
Like Loading...
Michele Solis 
CAR-T therapies have been licensed in the UK since 2018 for the treatment of B cell lymphoma. But with positive results emerging for their use in multiple myeloma, and the promise of potential in solid tumours, excitement around CAR-T continues to grow.
Read this story at Pharmaceutical Journal.
Like this: